- Home
- APLT vs PHVS Comparison
APLT vs PHVS Comparison
Compare APLT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- PHVS
- Stock Information
- Founded
- APLT 2016
- PHVS 2015
- Country
- APLT United States
- PHVS Switzerland
- Employees
- APLT N/A
- PHVS N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- PHVS Health Care
- Exchange
- APLT Nasdaq
- PHVS Nasdaq
- Market Cap
- APLT 52.9M
- PHVS 980.3M
- IPO Year
- APLT 2019
- PHVS 2021
- Fundamental
- Price
- APLT $0.33
- PHVS $18.60
- Analyst Decision
- APLT Buy
- PHVS Buy
- Analyst Count
- APLT 7
- PHVS 6
- Target Price
- APLT $6.10
- PHVS $37.17
- AVG Volume (30 Days)
- APLT 2.3M
- PHVS 35.9K
- Earning Date
- APLT 08-06-2025
- PHVS 08-13-2025
- Dividend Yield
- APLT N/A
- PHVS N/A
- EPS Growth
- APLT N/A
- PHVS N/A
- EPS
- APLT N/A
- PHVS N/A
- Revenue
- APLT $265,000.00
- PHVS N/A
- Revenue This Year
- APLT $1,768.13
- PHVS N/A
- Revenue Next Year
- APLT $292.85
- PHVS N/A
- P/E Ratio
- APLT N/A
- PHVS N/A
- Revenue Growth
- APLT N/A
- PHVS N/A
- 52 Week Low
- APLT $0.30
- PHVS $11.51
- 52 Week High
- APLT $10.62
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- APLT 43.25
- PHVS 60.00
- Support Level
- APLT $0.30
- PHVS $16.72
- Resistance Level
- APLT $0.36
- PHVS $17.53
- Average True Range (ATR)
- APLT 0.03
- PHVS 0.93
- MACD
- APLT -0.00
- PHVS 0.07
- Stochastic Oscillator
- APLT 22.22
- PHVS 92.86
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.